Takashi Makino1, Tetuo Mikami2, Yoshinobu Hata1, Hajime Otsuka1, Satoshi Koezuka1, Kazutoshi Isobe3, Naobumi Tochigi4, Kazutoshi Shibuya4, Sakae Homma3, Akira Iyoda5. 1. Division of Chest Surgery, Toho University School of Medicine, Tokyo, Japan. 2. Department of Pathology, Toho University School of Medicine, Tokyo, Japan. 3. Division of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. 4. Department of Surgical Pathology, Toho University School of Medicine, Tokyo, Japan. 5. Division of Chest Surgery, Toho University School of Medicine, Tokyo, Japan. Electronic address: aiyoda@med.toho-u.ac.jp.
Abstract
BACKGROUND: The prognosis for patients with large cell neuroendocrine carcinoma (LCNEC) of the lung is extremely poor, and optimal treatment strategies have not yet been established. To improve prognoses in patients with LCNEC, this study analyzed immunohistochemical expression and gene mutations of several known molecular targets in LCNECs and compared the expression levels of these targets with those in lung adenocarcinomas. METHODS: Twenty-six patients with primary LCNEC and 40 patients with adenocarcinoma were analyzed. Excision repair cross-complementation group 1 (ERCC1), class III β-tubulin, topoisomerase I, topoisomerase II, epidermal growth factor receptor (EGFR)-L858R, and somatostatin receptor expression were evaluated by immunohistochemistry, and EGFR mutations were evaluated using direct DNA sequencing and the Scorpion-amplified refractory mutation system. RESULTS: In patients with LCNEC and adenocarcinoma, positive rates of topoisomerase I, topoisomerase II, ERCC1, class III β-tubulin, EGFR-L858R, and somatostatin were 100.0% and 100.0%, 65.4% and 15.0% (p < 0.0001), 42.3% and 17.5% (p = 0.0462), 46.2% and 62.5%, 0.0% and 20.0% (p = 0.0182), and 50.0% and 5.0% (p < 0.0001), respectively. The frequencies of EGFR mutations were 0.0% and 37.5% in LCNEC and adenocarcinoma (p = 0.0002), respectively. Five-year overall survival rates were 64% in LCNEC and 91% in adenocarcinoma in stage I (p = 0.0132). Multivariate analysis showed that LCNEC histologic type was an independent prognostic factor in stage I. CONCLUSIONS: LCNEC showed overexpression of topoisomerase II, somatostatin, and ERCC1. These findings suggested that it was possible to have good response to treatment with etoposide and octreotide and that LCNEC may be resistant to platinum-based therapy compared with adenocarcinoma. EGFR mutations were not observed in LCNEC. These results may indicate a favorable response to adjuvant treatments that are not typically prescribed for non-small cell lung cancer.
BACKGROUND: The prognosis for patients with large cell neuroendocrine carcinoma (LCNEC) of the lung is extremely poor, and optimal treatment strategies have not yet been established. To improve prognoses in patients with LCNEC, this study analyzed immunohistochemical expression and gene mutations of several known molecular targets in LCNECs and compared the expression levels of these targets with those in lung adenocarcinomas. METHODS: Twenty-six patients with primary LCNEC and 40 patients with adenocarcinoma were analyzed. Excision repair cross-complementation group 1 (ERCC1), class III β-tubulin, topoisomerase I, topoisomerase II, epidermal growth factor receptor (EGFR)-L858R, and somatostatin receptor expression were evaluated by immunohistochemistry, and EGFR mutations were evaluated using direct DNA sequencing and the Scorpion-amplified refractory mutation system. RESULTS: In patients with LCNEC and adenocarcinoma, positive rates of topoisomerase I, topoisomerase II, ERCC1, class III β-tubulin, EGFR-L858R, and somatostatin were 100.0% and 100.0%, 65.4% and 15.0% (p < 0.0001), 42.3% and 17.5% (p = 0.0462), 46.2% and 62.5%, 0.0% and 20.0% (p = 0.0182), and 50.0% and 5.0% (p < 0.0001), respectively. The frequencies of EGFR mutations were 0.0% and 37.5% in LCNEC and adenocarcinoma (p = 0.0002), respectively. Five-year overall survival rates were 64% in LCNEC and 91% in adenocarcinoma in stage I (p = 0.0132). Multivariate analysis showed that LCNEC histologic type was an independent prognostic factor in stage I. CONCLUSIONS:LCNEC showed overexpression of topoisomerase II, somatostatin, and ERCC1. These findings suggested that it was possible to have good response to treatment with etoposide and octreotide and that LCNEC may be resistant to platinum-based therapy compared with adenocarcinoma. EGFR mutations were not observed in LCNEC. These results may indicate a favorable response to adjuvant treatments that are not typically prescribed for non-small cell lung cancer.
Authors: José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata Journal: Mol Diagn Ther Date: 2018-04 Impact factor: 4.074
Authors: Jin-Yan Liang; Fan Tong; Fei-Fei Gu; Yang-Yang Liu; Yu-Lan Zeng; Xiao-Hua Hong; Kai Zhang; Li Liu Journal: Medicine (Baltimore) Date: 2017-05 Impact factor: 1.889
Authors: Arsela Prelaj; Sara Elena Rebuzzi; Gabriella Del Bene; Julio Rodrigo Giròn Berrìos; Alessandra Emiliani; Lucilla De Filippis; Alessandra Anna Prete; Silvia Pecorari; Gaia Manna; Carla Ferrara; Daniele Rossini; Flavia Longo Journal: ERJ Open Res Date: 2017-03-29
Authors: Tatiana N Zamay; Galina S Zamay; Olga S Kolovskaya; Ruslan A Zukov; Marina M Petrova; Ana Gargaun; Maxim V Berezovski; Anna S Kichkailo Journal: Cancers (Basel) Date: 2017-11-13 Impact factor: 6.639